Dr. Reddy’s re-appoints G V Prasad as Co-Chairman and Managing Director
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Subscribe To Our Newsletter & Stay Updated